Vonoprazan in the management of erosive oesophagitis and peptic ulcer-induced medication: a systematic review.

Autor: Chinzon D; Department of Gastroenterology, University of Sao Paulo, Sao Paulo, Brazil., Moraes-Filho JPP; Department of Gastroenterology, University of Sao Paulo, Sao Paulo, Brazil., Domingues G; Department of Gastroenterology, State University of Rio de Janeiro, Rio de Janeiro, Brazil., Guedes JLS; Takeda Pharmaceuticals Brazil., Santos CY; Takeda Pharmaceuticals Brazil., Zaterka S; Department of Gastroenterology, University of Sao Paulo, Sao Paulo, Brazil.
Jazyk: angličtina
Zdroj: Przeglad gastroenterologiczny [Prz Gastroenterol] 2022; Vol. 17 (3), pp. 183-189. Date of Electronic Publication: 2021 Dec 08.
DOI: 10.5114/pg.2021.111401
Abstrakt: Introduction: Vonoprazan has been found to promote a better antisecretory effect addressing acid-related diseases' unmet needs.
Aim: To assess if vonoprazan effectively treats patients diagnosed with gastroesophageal reflux disease esophagitis or with peptic ulcers induced by chronic use of aspirin or non-steroidal anti-inflammatory drugs.
Material and Methods: A literature search was conducted (April/2021) using Medline via PubMed, Cochrane library, Lilacs, Scielo, and Centre for Reviews and Dissemination electronic databases.
Results: We retrieved 55 titles. Of these, 13 met the eligibility criteria and were included in this review. Of these 13 articles, 4 were prospective cohort studies, 1 was a follow-up analysis of a preceding prospective study, 1 was a retrospective cohort study, and 6 were randomized clinical trials.
Conclusions: Our findings suggest that vonoprazan was effective and non-inferior to proton pump inhibitors in healing and maintaining healed reflux oesophagitis, leading to faster symptom relief. Vonoprazan may also be considered for preventing aspirin- or non-steroidal anti-inflammatory drug-related peptic ulcer recurrence.
Competing Interests: DC has received fees as advisory board member for Takeda. JPPMF and GD has received fees as speaker for Takeda. JLSG and CYS are Takeda Pharmaceuticals Brazil full-time employees. Takeda Pharmaceuticals Brazil funded this work.
(Copyright © 2022 Termedia.)
Databáze: MEDLINE
Externí odkaz: